Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)-Reference-Cited by-同舟云学术

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

Published:2011-11-13 Issue:17 Volume:25 Page:2113-2122
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Taiwo Babafemi,Zheng Lu,Gallien Sebastien,Matining Roy M.,Kuritzkes Daniel R.,Wilson Cara C.,Berzins Baiba I.,Acosta Edward P.,Bastow Barbara,Kim Peter S.,Eron Joseph J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference21 articles.

1. Effect of transmitted resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.;Wittkop;Lancet Infect Dis,2011

2. Class-sparing regimens for initial treatment of HIV-1 infection.;Riddler;N Engl J Med,2008

3. Once-daily darunavirritonavir vs. lopinavirritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.;Mills;AIDS,2009

4. Raltegravir versus efavirenz regimens in treatment-naive HIV-1 infected patients: 96 week efficacy, durability, subgroup, safety and metabolic analyses.;Lennox;J Acquir Immune Defic Syndr,2010

5. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instrument. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).;Chesney;AIDS Care,2000

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure;Drug Design, Development and Therapy;2024-04

2. Two-drug regimens for HIV treatment;The Lancet HIV;2022-12

3. Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV;African Health Sciences;2022-10-28

4. Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial;2022-07-09

5. Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan;PLOS ONE;2022-06-14